Kringle Pharma, Inc. (TYO:4884)

Japan · Delayed Price · Currency is JPY

597.00

-14.00 (-2.29%)

Oct 26, 2026, 3:30 PM JST

Market Cap	5.00B +62.7%
Revenue (ttm)	342.21M +372.4%
Net Income	-808.44M
EPS	-110.24
Shares Out	8.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,400
Open	605.00
Previous Close	611.00
Day's Range	585.00 - 607.00
52-Week Range	287.00 - 741.00
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About Kringle Pharma

Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 17

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4884

Full Company Profile

Financial Performance

In fiscal year 2025, Kringle Pharma's revenue was 72.00 million, a decrease of -10.00% compared to the previous year's 80.00 million. Losses were -916.00 million, 21.2% more than in 2024.

Financial Statements